INBRAIN Neuroelectronics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 35)
INBRAIN Neuroelectronics logo

INBRAIN Neuroelectronics

NicheLife Sciences & BioTech

Graphene Neural Interface & Brain Stimulation

INBRAIN Neuroelectronics develops graphene-based brain-computer interfaces for AI-driven, adaptive neuromodulation; raised €30M Series B in 2024; targeting Parkinson's, epilepsy, and psychiatric disorders;

AI VisibilityBeta
Overall Score
D35
Category Rank
#121 of 198
AI Consensus
90%
Trend
stable
Per Platform
ChatGPT
32
Perplexity
33
Gemini
30

About

INBRAIN Neuroelectronics is a neurotechnology company founded in 2019 as a spin-out from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, Spain. The company develops minimally invasive brain-computer interfaces built on graphene — a single layer of carbon atoms with exceptional electrical conductivity, biocompatibility, and transparency to MRI imaging. INBRAIN's graphene electrodes enable higher spatial resolution neural sensing and more precise, adaptive stimulation than conventional metal electrodes used in implantable neurostimulators.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#121
Category Rank
#11
90
AI Consensus
68
stable
Trend
stable
32
ChatGPT
71
33
Perplexity
68
30
Gemini
80
33
Claude
77
30
Grok
69

Key Details

Category
Graphene Neural Interface & Brain Stimulation
AI-Enabled Precision Medicine
Tier
Niche
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.